This content is machine translated Hodgkin's lymphoma Does brentuximab vedotin have curative potential in a subset of affected individuals? New results from a phase II study presented at the ASH Congress in New Orleans offer hope for patients with refractory or relapsed Hodgkin’s lymphoma: Approximately 10% of participants in…
View Post 3 min This content is machine translated Newly diagnosed multiple myeloma Does a proteasome inhibitor offer new therapeutic options? One study discussed at the ASH meeting involved a regimen consisting of oral MLN9708 administered twice weekly plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. It concludes…
View Post 4 min This content is machine translated Multiple Myeloma and MDS Something has happened in therapy The diagnosis and treatment of multiple myeloma (MM) and myelodysplastic syndromes (MDS) have undergone great development in recent years. Modern diagnostic procedures became qualitatively better and more widely available, new…
View Post 4 min This content is machine translated Chronic lymphocytic leukemia New therapies urgently needed At the ESMO Congress in Amsterdam, speakers from various countries discussed the latest results and therapy recommendations in the field of chronic lymphocytic leukemia. Overall, chemoimmunotherapy with fludarabine, cyclophosphamide (FC),…
View Post 5 min This content is machine translated Non-Hodgkin's Lymphoma “The new drugs will fundamentally change the therapeutic landscape” In an interview with InFo ONCOLOGY & HEMATOLOGY, Prof. Christoph Driessen, MD, Head Physician of the Department of Oncology/Hematology at the Cantonal Hospital St. Gallen, provides information on the pathogenesis,…
